Reminder to Ultragenyx Pharmaceutical (RARE) Investors Regarding Securities Issues by Faruqi & Faruqi, LLP

A prominent national law firm, Faruqi & Faruqi, LLP, has taken a significant step in supporting Ultragenyx Pharmaceutical Inc (“Ultragenyx” or the “Company”) by urging investors who have incurred losses exceeding $100,000 in the Company between August 3, 2023, and December 26, 2025, to engage directly in discussions with their Securities Litigation Partner, James (Josh) Wilson. The deadline for Ultragenyx investors to seek the role of lead plaintiff in a federal securities class action is April 6, 2026.

Faruqi & Faruqi is a well-known national law firm with offices in New York, Pennsylvania, California, and Georgia, having successfully recovered substantial amounts for investors since its establishment in 1995. The firm is investigating potential claims against Ultragenyx Pharmaceutical Inc concerning alleged misrepresentation and nondisclosure by the Company and its executives of key information to investors.

The complaint brought against Ultragenyx highlights the assertion that the Company and its executives violated federal securities laws by creating a false impression about their knowledge of setrusumab’s effects on patients with Osteogenesis Imperfecta (“OI”). Additionally, they allegedly downplayed the risk that patients in Ultragenyx’s Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate (“AFR”).

The issue further centers on the Company’s inadequate conveyance of risks associated with benchmarking the Phase III Orbit study’s results and interim analysis on Phase II results that lacked a placebo control group for a valid comparison. The complaint contends that Ultragenyx’s optimism regarding the study’s results was misplaced due to various factors influencing the data interpretation.

On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study had not achieved statistical significance for the second interim analysis. This news led to a significant decline in Ultragenyx’s stock price, plummeting by over 25%. Moreover, on December 29, 2025, Ultragenyx announced the failure of both its Phase III Orbit and Cosmic Studies to reach statistical significance against primary endpoints. Subsequently, the stock price plunged by more than 42%.

The role of the court-appointed lead plaintiff in the class action is pivotal, as this individual will represent the interests of the class members and oversee the litigation process. Any member of the potential class may seek to be the lead plaintiff with their chosen legal counsel or opt to remain an absent class member. The decision to serve as a lead plaintiff does not impact an individual’s eligibility to partake in any future recovery resulting from the litigation.

Faruqi & Faruqi, LLP not only calls for anyone with relevant information on Ultragenyx’s conduct to reach out, including whistleblowers, former employees, and shareholders, but also emphasizes the importance of investors affected by the alleged misconduct to seek assistance.

Overall, the legal proceedings against Ultragenyx Pharmaceutical Inc illustrate the critical role of investors in holding corporations accountable for ensuring transparency and adherence to federal securities laws governing fair market practices. Faruqi & Faruqi’s expertise in financial litigation supports the pursuit of justice for investors who have suffered substantial losses due to alleged corporate wrongdoing.